Pelthos Therapeutics Inc (PTHS)

AMEXHealth CareBiotechnologySnapshot 2026-10-23

$17.00-13.22%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Pelthos Therapeutics Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	18.71M
EPS	—	-2.78
Annual ending 2026-12-31
Revenue	—	62.87M
EPS	—	-16.201
Annual ending 2027-12-31
Revenue	—	110.3M
EPS	—	-4.226

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage ongoing litigation and regulatory challenges	A primary condition in Pelthos Therapeutics Inc's published investment case. The stated target is No new major litigation filings and resolution of existing cases by end of 2026.	Under Pressure	New significant litigation filings or regulatory penalties occur after mid-2026	2 new litigation filings (May & Aug 2026) vs 0 target Form 8-K filings in May and August 2026 disclose new litigation, alongside an accounting restatement and material weakness. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Management disclosed ongoing legal and regulatory challenges including litigation filings and a material weakness in internal controls related to ASC 820. These issues remain active with no resolution reported, indicating ongoing management focus but limited progress. Delivery assessment Oct 24, 2026
Stabilize executive leadership	The company recently promoted a new CFO to stabilize leadership.	Under Pressure	Additional key executive departures or leadership turmoil occur in FY26	1 executive departure event vs 0 target Form 8-K Item 5.02 filed Oct 1, 2026 reports an officer change, indicating a new executive departure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management managed CFO transition with termination in May 2026 and promotion of new CFO in April 2026. This indicates active handling of leadership changes to maintain stability. Delivery assessment Oct 24, 2026
Growth of ZELSUVMI product sales	Pelthos aims to grow sales of its ZELSUVMI product, which management prioritizes.	Broken	revenue falls below $7 million in FY25 or fails to grow toward $121 million by FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Zelsuvmi net product revenue increased from $9.1 million in 2025-Q4 to $10.7 million in 2026-Q1 (+17%), then to $15.4 million in 2026-Q2 (+45%). Units dispensed also rose 48% quarter-over-quarter in Q2 2026. Management is delivering on growth with accelerating revenue and prescription volume. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.23

Unavailable → $-4.23 · observed estimates

FY2027 revenue$0.11B

$0.12B → $0.11B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$120,246,667	4 / 5
2026-07-25	Unavailable	$120,246,667	4 / 5
2026-07-26	Unavailable	$120,246,667	4 / 5
2026-07-27	Unavailable	$120,246,667	4 / 5
2026-07-28	Unavailable	$120,246,667	4 / 5
2026-07-29	Unavailable	$120,246,667	4 / 5
2026-07-30	Unavailable	$120,246,667	4 / 5
2026-07-31	Unavailable	$120,246,667	4 / 5
2026-08-01	Unavailable	$120,246,667	4 / 5
2026-08-02	Unavailable	$120,246,667	4 / 5
2026-08-03	Unavailable	$120,246,667	4 / 5
2026-08-04	Unavailable	$120,246,667	4 / 5
2026-08-05	Unavailable	$120,246,667	4 / 5
2026-08-06	Unavailable	$121,180,000	4 / 6
2026-08-07	Unavailable	$120,246,667	4 / 5
2026-08-08	Unavailable	$121,180,000	4 / 6
2026-08-09	Unavailable	$121,180,000	4 / 6
2026-08-10	Unavailable	$121,180,000	4 / 6
2026-08-12	Unavailable	$121,180,000	4 / 6
2026-08-13	Unavailable	$121,180,000	4 / 6
2026-08-14	Unavailable	$120,246,667	4 / 5
2026-08-15	Unavailable	$120,246,667	4 / 5
2026-08-16	Unavailable	$120,246,667	4 / 5
2026-08-17	Unavailable	$120,246,667	4 / 5
2026-08-18	Unavailable	$120,246,667	4 / 5
2026-08-19	Unavailable	$120,246,667	4 / 5
2026-08-20	$-3.90	$112,217,286	5 / 6
2026-08-21	$-3.90	$112,217,286	5 / 6
2026-08-22	$-3.90	$112,217,286	5 / 6
2026-08-23	$-3.90	$112,217,286	5 / 6
2026-08-24	$-3.90	$112,217,286	5 / 6
2026-08-25	$-3.90	$112,217,286	5 / 6
2026-08-26	$-3.90	$112,217,286	5 / 6
2026-08-27	$-3.90	$112,217,286	5 / 6
2026-08-28	$-3.90	$112,217,286	5 / 6
2026-08-29	$-3.90	$112,217,286	5 / 6
2026-08-30	$-3.90	$112,217,286	5 / 6
2026-08-31	$-3.90	$112,217,286	5 / 6
2026-09-01	$-3.90	$112,217,286	5 / 6
2026-09-02	$-3.90	$112,217,286	5 / 6
2026-09-03	$-3.90	$112,217,286	5 / 6
2026-09-04	$-3.90	$112,217,286	5 / 6
2026-09-05	$-3.90	$112,217,286	5 / 6
2026-09-06	$-3.90	$112,217,286	5 / 6
2026-09-07	$-3.90	$112,217,286	5 / 6
2026-09-08	$-3.90	$112,217,286	5 / 6
2026-09-09	$-3.90	$112,217,286	5 / 6
2026-09-10	$-3.90	$112,217,286	5 / 6
2026-09-11	$-3.90	$112,217,286	5 / 6
2026-09-12	$-3.90	$112,218,000	5 / 6
2026-09-13	$-3.90	$112,218,000	5 / 6
2026-09-14	$-3.90	$112,218,000	5 / 6
2026-09-15	$-3.90	$112,218,000	5 / 6
2026-09-16	$-3.90	$112,218,000	5 / 6
2026-09-17	$-3.90	$112,218,000	5 / 6
2026-09-18	$-3.90	$112,218,000	5 / 6
2026-09-19	$-3.90	$112,218,000	5 / 6
2026-09-20	$-3.90	$112,218,000	5 / 6
2026-09-21	$-3.90	$112,218,000	5 / 6
2026-09-22	$-3.90	$112,218,000	5 / 6
2026-09-23	$-3.90	$112,218,000	5 / 6
2026-09-24	$-3.90	$112,218,000	5 / 6
2026-09-25	$-3.90	$112,218,000	5 / 6
2026-09-26	$-3.90	$112,218,000	5 / 6
2026-09-27	$-3.90	$112,218,000	5 / 6
2026-09-28	$-3.90	$112,218,000	5 / 6
2026-09-29	$-3.90	$112,218,000	5 / 6
2026-09-30	$-3.90	$112,218,000	5 / 6
2026-10-01	$-3.90	$112,218,000	5 / 6
2026-10-02	$-3.90	$112,218,000	5 / 6
2026-10-03	$-3.90	$112,218,000	5 / 6
2026-10-04	$-3.90	$112,218,000	5 / 6
2026-10-05	$-3.90	$112,218,000	5 / 6
2026-10-06	$-3.90	$112,218,000	5 / 6
2026-10-07	$-3.90	$112,218,000	5 / 6
2026-10-08	$-3.90	$112,218,000	5 / 6
2026-10-09	$-3.90	$112,218,000	5 / 6
2026-10-10	$-3.90	$112,218,000	5 / 6
2026-10-11	$-3.90	$112,218,000	5 / 6
2026-10-12	$-3.90	$112,218,000	5 / 6
2026-10-13	$-4.23	$110,303,714	5 / 6
2026-10-14	$-4.23	$110,303,714	5 / 6
2026-10-15	$-4.23	$110,303,714	5 / 6
2026-10-16	$-4.23	$110,303,714	5 / 6
2026-10-17	$-4.23	$110,303,714	5 / 6
2026-10-18	$-4.23	$110,303,714	5 / 6
2026-10-19	$-4.23	$110,303,714	5 / 6
2026-10-20	$-4.23	$110,303,714	5 / 6
2026-10-21	$-4.23	$110,303,714	5 / 6
2026-10-22	$-4.23	$110,303,714	5 / 6
2026-10-23	$-4.23	$110,303,714	5 / 6
2026-10-24	$-4.23	$110,303,714	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	7	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Lake StreetOct 12

$40.00New observation · no comparable prior

$0$22.00$44.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage ongoing litigation and regulatory challengesPublished status: Under Pressure
Stabilize executive leadershipPublished status: Under Pressure
Growth of ZELSUVMI product salesPublished status: Broken

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-54.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Pelthos Therapeutics Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making commercialization story, not a proven durable compounder. The thesis is on watch, and confidence is low after a recent earnings miss and negative legal and regulatory events.

What's priced into Pelthos Therapeutics Inc

The evidence snapshot provides no valuation multiple or explicit account of market expectations, so whether PTHS is cheap or expensive versus peers is unclear. No valuation fragility signals fired, but that does not resolve the uncertainty around expectations.

What the fundamentals likely do

Near term, an earnings miss risk is elevated, and the recent financial performance is weak relative to its industry cohort. Zelsuvmi revenue and units dispensed have grown, while planned Xepi and Xeglyze launches remain ahead and have no financial results yet. Cash declined in Q2, though a loan facility provides some capital flexibility.

What Pelthos Therapeutics Inc hinges on

The multi-year thesis hinges on continued Zelsuvmi growth, execution on the planned 2027 launches, and enough capital to support commercialization. Near term, a guidance cut or continued job-market weakening would add pressure; continued earnings strength from sector peers could support the broader Healthcare backdrop.